Institute Of Hematology & Blood Diseases Hospital, China
Clinical trials sponsored by Institute Of Hematology & Blood Diseases Hospital, China, explained in plain language.
-
New attack plan for rare leukemia: CAR-T cells + stem cell transplant
Disease control OngoingThis study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
CAR-T therapy for tough arthritis cases – study pulled before start
Disease control TerminatedThis study was designed to test the safety and effectiveness of a new treatment called GC012F for people with difficult-to-treat rheumatoid arthritis. It planned to enroll adults aged 18 to 75 whose arthritis did not respond well to standard therapies. However, the study was with…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New attack plan for tough myeloma: immune cells + transplant shows promise
Disease control OngoingThis phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell trans…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for elderly leukemia patients: which chemo works best?
Disease control OngoingThis study aims to find the safest and most effective initial chemotherapy for older adults (60-75) newly diagnosed with acute myeloid leukemia who can handle strong treatment. About 90 participants will be randomly assigned to one of two drug combinations or a standard treatment…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for T-ALL: drug clears hidden cancer cells after chemo
Disease control TerminatedThis study tests the drug daratumumab in adults with T-cell acute lymphoblastic leukemia (T-ALL) who still have tiny amounts of cancer cells (called minimal residual disease, or MRD) after standard chemotherapy. The goal is to see if daratumumab can clear these leftover cells and…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising leukemia combo trial pulled before it even started
Disease control TerminatedThis trial aimed to test a new drug called CM313, a CD38-targeting antibody, combined with a chemotherapy regimen inspired by pediatric treatments for adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). The goal was to see if the combination could improve rem…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail shows promise against rare blood cancer
Disease control OngoingThis study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see if this approach can shrink or elim…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New chemo cocktail aims to boost survival in elderly leukemia patients
Disease control OngoingThis phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
CAR-T therapy aimed at High-Risk myeloma patients after transplant — study withdrawn
Disease control TerminatedThis study planned to test a type of immunotherapy called BCMA CAR-T cells in people with high-risk multiple myeloma who still had signs of cancer after a stem cell transplant. The goal was to see if the treatment could clear remaining cancer cells and improve outcomes. However, …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody therapy targets Hard-to-Treat AL amyloidosis
Disease control TerminatedThis trial aimed to test an experimental drug called CM-336 for people with AL amyloidosis that has returned, not responded to treatment, or only partially responded after initial therapy. The drug works by helping the immune system attack and destroy harmful cells. However, the …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could cord blood transplants slow ALS? new trial begins
Disease control ENROLLING_BY_INVITATIONThis early trial tests whether a transplant of umbilical cord blood can help people with ALS, a fast-progressing nerve disease. Eight adults will receive the transplant after a mild chemotherapy-like prep. Researchers will check safety and whether the treatment slows decline in m…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug aims to wipe out lingering leukemia cells after chemo
Disease control OngoingThis phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Double attack on lymphoma: antibody plus CAR-T combo shows promise
Disease control OngoingThis study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Leukemia relapse predictor study pulled before starting
Knowledge-focused TerminatedThis study aimed to see if tracking a specific gene mutation (c-Kit) could help predict relapse in acute myeloid leukemia patients. It planned to compare this method with current monitoring techniques. However, the study was withdrawn before enrolling any participants, so no resu…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive hemophilia study aims to uncover hidden costs and care gaps in china
Knowledge-focused OngoingThis study is observing 500 male patients aged 12 and older with severe hemophilia A or B across China. Researchers are collecting data on treatment patterns, costs, and quality of life to understand the true burden of the disease. The goal is to identify gaps in care and help im…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Cord blood bank launches massive health tracking study
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow 2,000 people who have stored umbilical cord blood at the Tianjin Cord Blood Bank. Researchers will check in on participants' health status over time to see how they are doing. No treatments or interventions are being tested—this is purely a da…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC